Is there a role for starting an anabolic agent in a patient that developed an atypical femoral fracture while on denosumab sooner than 6 months after the last denosumab dose?  

The biology of an AFF is still being elucidated. However, there are many aspects of an AFF that are similar to a "stress fracture" in that there is a combination of osteoid and cartilage that does not fully mineralize. Fracture healing goes through a cartilaginous phase, followed by mineralization w...

This is an interesting question on several levels. There is evidence that transitioning from denosumab to teriparatide may result in some decrease in hip bone density as well as compromised hip bone strength and therefore, that sequence of treatments should be avoided. There is less compelling evide...